Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows
Portfolio Pulse from Vandana Singh
SELLAS Life Sciences Group Inc (SLS) released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S (GPS), combined with Bristol Myers Squibb Co's (BMY) nivolumab in patients with malignant pleural mesothelioma. The results showed improved survival rates with no dose-limiting toxicities observed. However, SLS shares are down 1.22%.
June 28, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bristol Myers Squibb's nivolumab was used in combination with SELLAS's GPS in a Phase 1 trial that showed improved survival rates in lung cancer patients.
The successful trial results could potentially increase the demand for BMY's nivolumab, especially if it continues to be used in combination with SLS's GPS. However, the impact on BMY's stock price is uncertain as the news is more focused on SLS.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
SELLAS's Phase 1 trial results show improved survival rates in lung cancer patients, which could potentially boost the company's reputation and future sales. However, the stock price is currently down.
The positive results from the Phase 1 trial could potentially increase the demand for SLS's product, leading to higher future sales. However, the current drop in stock price indicates that the market may not have fully absorbed this news yet.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100